Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study

The aim of this investigation was to determine the effect of SARS-Cov-2 vaccination in hemodialysis patients, search for risk factors for non- or low-response, and to measure the effect of a third booster vaccination in non- or low-responders. Methods SARS-CoV-2 IgG antibodies and the virus-neutrali...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Frank-Peter Tillmann, Lars Figiel, Johannes Ricken, Hermann Still, Christoph Korte, Grete Plassmann, Philipp von Landenberg
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	SARS-CoV-2 COVID-19 vaccination neutralizing antibodies antibody titer hemodialysis Medicine R
Acceso en línea:	https://doaj.org/article/5abc5b6bdb134b22b47628cb27d5006e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5abc5b6bdb134b22b47628cb27d5006e
record_format	dspace
spelling	oai:doaj.org-article:5abc5b6bdb134b22b47628cb27d5006e2021-11-11T17:43:55ZEvolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study10.3390/jcm102151132077-0383https://doaj.org/article/5abc5b6bdb134b22b47628cb27d5006e2021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/5113https://doaj.org/toc/2077-0383The aim of this investigation was to determine the effect of SARS-Cov-2 vaccination in hemodialysis patients, search for risk factors for non- or low-response, and to measure the effect of a third booster vaccination in non- or low-responders. Methods SARS-CoV-2 IgG antibodies and the virus-neutralizing capacity were measured 4–5 weeks after a full standard vaccination in 95 chronic hemodialysis patients and 60 controls. IgG titers > 30 AU/mL served to classify participants as responders. Multivariable binary logistic regression analysis was used to search for risk factors of reduced vaccination success. Patients with vaccination failure were offered a third booster dosage. Results 82.1% of the patient cohort as compared to 98.3% of the healthy control group were able to mount SARS-CoV-2 titers above 30 AU/mL after two standard vaccine doses. Mean IgG antibody titers were lower in hemodialysis patients than controls (78 ± 35 vs. 90 ± 20 AU/mL, <i>p</i> = 0.002). Multivariable binary logistic regression analysis showed age and immunosuppressive medication as major risk factors for vaccination failure with a decreased probability of successful vaccination of −6.1% (95% CI −1.2 to −10.9) per increase in age of one year and −87.4% (95% CI −98.0 to −21.5) in patients on immunosuppressive therapy (crude odds ratio for vaccination failure for immunosuppressive therapy 6.4). Ten out of 17 patients with non-response to vaccination were offered a third dose. Booster vaccination after the second dose induced an increase in effective antibody titers of >30 AU/mL in seven out of ten patients 4–5 weeks later (70%). Conclusion Standard SARS-CoV-2 vaccination schemes are highly effective in mounting protective neutralizing IgG antibodies in chronic hemodialysis patients. Nevertheless, response to vaccination is diminished as compared to a healthy control group. Major risk factors for vaccination failure are older age and immunosuppressive therapy. In non- or low-responders to standard vaccination a third booster vaccination was able to induce effective antibody titers in about 70% of patients, indicating that a third booster vaccination might be preferable to decreasing immunosuppressive therapy.Frank-Peter TillmannLars FigielJohannes RickenHermann StillChristoph KorteGrete PlassmannPhilipp von LandenbergMDPI AGarticleSARS-CoV-2COVID-19vaccinationneutralizing antibodiesantibody titerhemodialysisMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5113, p 5113 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 COVID-19 vaccination neutralizing antibodies antibody titer hemodialysis Medicine R
spellingShingle	SARS-CoV-2 COVID-19 vaccination neutralizing antibodies antibody titer hemodialysis Medicine R Frank-Peter Tillmann Lars Figiel Johannes Ricken Hermann Still Christoph Korte Grete Plassmann Philipp von Landenberg Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study
description	The aim of this investigation was to determine the effect of SARS-Cov-2 vaccination in hemodialysis patients, search for risk factors for non- or low-response, and to measure the effect of a third booster vaccination in non- or low-responders. Methods SARS-CoV-2 IgG antibodies and the virus-neutralizing capacity were measured 4–5 weeks after a full standard vaccination in 95 chronic hemodialysis patients and 60 controls. IgG titers > 30 AU/mL served to classify participants as responders. Multivariable binary logistic regression analysis was used to search for risk factors of reduced vaccination success. Patients with vaccination failure were offered a third booster dosage. Results 82.1% of the patient cohort as compared to 98.3% of the healthy control group were able to mount SARS-CoV-2 titers above 30 AU/mL after two standard vaccine doses. Mean IgG antibody titers were lower in hemodialysis patients than controls (78 ± 35 vs. 90 ± 20 AU/mL, <i>p</i> = 0.002). Multivariable binary logistic regression analysis showed age and immunosuppressive medication as major risk factors for vaccination failure with a decreased probability of successful vaccination of −6.1% (95% CI −1.2 to −10.9) per increase in age of one year and −87.4% (95% CI −98.0 to −21.5) in patients on immunosuppressive therapy (crude odds ratio for vaccination failure for immunosuppressive therapy 6.4). Ten out of 17 patients with non-response to vaccination were offered a third dose. Booster vaccination after the second dose induced an increase in effective antibody titers of >30 AU/mL in seven out of ten patients 4–5 weeks later (70%). Conclusion Standard SARS-CoV-2 vaccination schemes are highly effective in mounting protective neutralizing IgG antibodies in chronic hemodialysis patients. Nevertheless, response to vaccination is diminished as compared to a healthy control group. Major risk factors for vaccination failure are older age and immunosuppressive therapy. In non- or low-responders to standard vaccination a third booster vaccination was able to induce effective antibody titers in about 70% of patients, indicating that a third booster vaccination might be preferable to decreasing immunosuppressive therapy.
format	article
author	Frank-Peter Tillmann Lars Figiel Johannes Ricken Hermann Still Christoph Korte Grete Plassmann Philipp von Landenberg
author_facet	Frank-Peter Tillmann Lars Figiel Johannes Ricken Hermann Still Christoph Korte Grete Plassmann Philipp von Landenberg
author_sort	Frank-Peter Tillmann
title	Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study
title_short	Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study
title_full	Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study
title_fullStr	Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study
title_full_unstemmed	Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study
title_sort	evolution of sars-cov-2-neutralizing antibodies after two standard dose vaccinations, risk factors for non-response and effect of a third dose booster vaccination in non-responders on hemodialysis: a prospective multi-centre cohort study
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/5abc5b6bdb134b22b47628cb27d5006e
work_keys_str_mv	AT frankpetertillmann evolutionofsarscov2neutralizingantibodiesaftertwostandarddosevaccinationsriskfactorsfornonresponseandeffectofathirddoseboostervaccinationinnonrespondersonhemodialysisaprospectivemulticentrecohortstudy AT larsfigiel evolutionofsarscov2neutralizingantibodiesaftertwostandarddosevaccinationsriskfactorsfornonresponseandeffectofathirddoseboostervaccinationinnonrespondersonhemodialysisaprospectivemulticentrecohortstudy AT johannesricken evolutionofsarscov2neutralizingantibodiesaftertwostandarddosevaccinationsriskfactorsfornonresponseandeffectofathirddoseboostervaccinationinnonrespondersonhemodialysisaprospectivemulticentrecohortstudy AT hermannstill evolutionofsarscov2neutralizingantibodiesaftertwostandarddosevaccinationsriskfactorsfornonresponseandeffectofathirddoseboostervaccinationinnonrespondersonhemodialysisaprospectivemulticentrecohortstudy AT christophkorte evolutionofsarscov2neutralizingantibodiesaftertwostandarddosevaccinationsriskfactorsfornonresponseandeffectofathirddoseboostervaccinationinnonrespondersonhemodialysisaprospectivemulticentrecohortstudy AT greteplassmann evolutionofsarscov2neutralizingantibodiesaftertwostandarddosevaccinationsriskfactorsfornonresponseandeffectofathirddoseboostervaccinationinnonrespondersonhemodialysisaprospectivemulticentrecohortstudy AT philippvonlandenberg evolutionofsarscov2neutralizingantibodiesaftertwostandarddosevaccinationsriskfactorsfornonresponseandeffectofathirddoseboostervaccinationinnonrespondersonhemodialysisaprospectivemulticentrecohortstudy
_version_	1718432002395340800

Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study

Ejemplares similares